Isoniazid (INH; 300 mg PO q24h) exerts bactericidal effects by interfering with the synthesis of lipid components of the mycobacterial cell wall. INH is a component of most TB treatment regimens and can be given twice a week in directly observed therapy (15 mg/kg/dose; 900 mg maximum). INH remains the drug of choice for treatment of latent TB infection (300 mg PO q24h for 9 mo or combined with rifapentine in a 12-wk regimen).

There's more to see -- the rest of this topic is available only to subscribers.